Idelalisib Completed Phase 1 Trials for Follicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia) / Small Lymphocytic Lymphoma (SLL) / Indolent Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Marginal Zone Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02242045Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia